Document Detail

Hematological and molecular response evaluation of CML patients on imatinib.
MedLine Citation:
PMID:  17571739     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. AIMS: To evaluate hematological and molecular response in CML patients on Imatinib and also the side effects of the therapy if any. METHODS AND MATERIALS: Sixteen patients were diagnosed as having chronic phase CML at Kasturba Medical College Hospital, Attavar, Mangalore during the period of two years from January 2004 to January 2006 and were given Imatinib at 400 mg/day orally. They were followed closely over a period of 1 year using the following parameters: (1) monthly clinical examination, (2) monthly peripheral blood smear examination, (3) real time reverse transcriptase quantitative polymerase chain reaction (RT Q-PCR) for BCR-ABL at the end of every 6 months. The findings were evaluated after one year for hematological and molecular response achieved. RESULTS: Fifteen (93.75%) patients achieved complete hematological response within three months of therapy. Six (37.5%) patients achieved complete molecular response(CMR) within six months of therapy as measured by real time RT Q-PCR. None of the patients who did not achieve CMR within first six months of therapy achieved it after one year of therapy. No patient lost the initial response. The median BCR--ABL/ABL value at the end of the six months was 11% and at the end of the one year was 3.38%. CONCLUSION: Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be usedas a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.
A Gupta; K Prasad
Related Documents :
24574849 - Review and redescription of species in the oecetis avara group, with the description of...
17571739 - Hematological and molecular response evaluation of cml patients on imatinib.
7693069 - Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis.
23847659 - Effect of 1α-25-dihydroxyvitamin d3 on intimal hyperplasia developing in vascular anast...
7819689 - Chronic childhood idiopathic thrombocytopenia purpura: long-term follow-up.
15801959 - Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? no ...
1804669 - One year treatment with almitrine improves hypoxaemia but does not increase pulmonary a...
20065369 - Outcomes of total knee arthroplasty in english- versus non-english-speaking patients.
11586559 - The role of antibiotics in the treatment of infectious diarrhea.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of the Association of Physicians of India     Volume:  55     ISSN:  0004-5772     ISO Abbreviation:  J Assoc Physicians India     Publication Date:  2007 Feb 
Date Detail:
Created Date:  2007-06-18     Completed Date:  2007-07-10     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  7505585     Medline TA:  J Assoc Physicians India     Country:  India    
Other Details:
Languages:  eng     Pagination:  109-13     Citation Subset:  IM    
Department of Medicine, Kasturba Medical College, Mangalore, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Antineoplastic Agents / pharmacology,  therapeutic use*
Fusion Proteins, bcr-abl / drug effects,  genetics
Gene Targeting
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  genetics,  pathology
Medical Oncology / trends
Middle Aged
Piperazines / adverse effects,  pharmacology,  therapeutic use*
Prospective Studies
Protein Kinase Inhibitors / adverse effects,  pharmacology,  therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / adverse effects,  pharmacology,  therapeutic use*
Reverse Transcriptase Polymerase Chain Reaction
Time Factors
Translocation, Genetic
Treatment Outcome*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Fusion Proteins, bcr-abl; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.1.-/Bcr-Abl tyrosine kinase; EC Kinases
Comment In:
J Assoc Physicians India. 2007 Feb;55:99-100   [PMID:  17571737 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal scor...
Next Document:  Accuracy of filter paper method for measuring glycated hemoglobin.